Current Status of Theranostics in Jordan
10.1007/s13139-018-0562-5
- Author:
Akram AL-IBRAHEEM
1
;
Ali MOHAMEDKHAIR
Author Information
1. Department of Nuclear Medicine, King Hussein Cancer Center, 202 Queen Rania St., P.O. Box 1269, Amman 11941, Jordan. aibraheem@khcc.jo
- Publication Type:Review
- From:Nuclear Medicine and Molecular Imaging
2019;53(1):7-10
- CountryRepublic of Korea
- Language:English
-
Abstract:
Exploring the unknown is one of the key factors that lead to great discoveries in mankind history.With the advances in medicine and the development of new approaches towards patient care, like next-generation sequencing and patient-centered care, the need for treatments tailored to patient through personalized medicine has become more compelling. Theranostics has been introduced as a combination of a diagnostic tool and a therapeutic tool on the same vector for a specific disease, to facilitate personalized medicine. Nuclear medicine has shown the capability of providing a strong platform for this new approach through its arms, molecular imaging, and targeted molecular therapies. Though the prototype of theranostics has been practiced in Jordan since decades in the field of diagnosis and treatment of well-differentiated thyroid cancer, recently, the King Hussein Cancer Center (KHCC), a leading and comprehensive cancer center in Jordan and in the Middle East, has leaped forward to introduce the new approaches of theranostics through the nuclear medicine applications. This paper sheds the light on the most important aspects of this new theranostics practice in Jordan such as peptide receptor radionuclide therapy (PRRT) and prostate-specific membrane antigen (PSMA)–based theranostics.
